Agility Robotics is thrilled to announce that we have successfully raised $150 million in our latest funding round, further solidifying our position at the forefront of humanoid robotics. Our company, founded on the premise of combining groundbreaking scientific research with exceptional engineering, has dedicated itself to creating robots that are not just innovative but also practical and function-driven. Since our inception, we have focused on developing humanoid robots that are designed for real-world applications, making strides in various sectors including logistics, elder care, and automated warehousing. This significant funding will allow us to accelerate the pace of our research and development, expand our team of talented engineers, and enhance our manufacturing capabilities. At Agility Robotics, we believe that intelligent machines can work alongside humans to improve productivity and quality of life. The infusion of capital will also empower us to advance our existing technologies, ensuring that our robots are equipped with the latest advancements in artificial intelligence and machine learning. With this new funding, we are excited to continue our mission of pushing the boundaries of what’s possible in robotics, ultimately creating humanoid robots that can seamlessly integrate into everyday environments and perform useful tasks, thus changing the way we think about work in the modern world. We are grateful to our investors for their belief in our vision and look forward to sharing our progress as we embark on this exciting journey together.
Agility Robotics Secures $150 Million in Funding to Advance Humanoid Robot Technologies
Get the full Agility Robotics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Anveshan
We are a food-tech startup aiming to provide high quality deeply traceable food products. We leverage technologies based on image processing, spectroscopy, blockchain and IOT to provide the best quality food products made traditionally.
$12.7M Series b
today
Caseway
We are the only enterprise AI form platform that replaces internal R&D and manual workflows by building and maintaining fully integrated automation systems, aligned to your data, your processes, and your long-term success. For document-intensive, compliance-driven organizations in regulated industries like insurance, education, finance, healthcare, and government Compelling reason to buy: Who need AI and automation tailored to their unique forms, workflows, and security environment, without having to shoulder R&D risk or manage AI development internally Product category: Our product is an enterprise document form platform Key benefit: That delivers a fully integrated, continuously improving automation system, built and maintained by experts, without upfront AI build costs Key differentiation: Our product is custom-built for each client’s systems and documents, fully integrated and continuously improved through a long-term partnership model, we maintain, debug, adapt, and align incentives to make it work in the real world.
$1.5M Pre-seed
today
Kubera Health
Kubera’s mission is to power a payment ecosystem where contracts are honored, care is rewarded, and waste is eliminated. We deliver contract and payment intelligence that unifies policies, terms, and claims data into one trusted platform — helping healthcare organizations and their partners build fairer contracts, ensure payments flow as intended, and align incentives across the care ecosystem. As healthcare shifts toward new reimbursement models and risk-sharing arrangements, Kubera is building the payment-intelligence backbone that enables multiple parties to adapt faster, protect margins, and dedicate more resources to patient care.
$6.5M Seed
today
Psilera
Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, Psilera has been focused on early-stage drug discovery & development with a dynamic team of experts in synthetic chemistry, pharmacology, clinical development, and business development.
$8.8M Seed
today
Abstract
Abstract is a venture capital firm based in San Francisco with $1.5 billion in assets under management. We are sector-agnostic, focused on seed and early stage founders. Our reputation among founders is built on fierce loyalty, unparalleled connections, and a relentless drive to help them win.
$59.0M Series a
today